Agios Pharmaceuticals AGIO Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's operating lease liabilities (current)?
- Agios Pharmaceuticals (AGIO) reported operating lease liabilities (current) of $18.81M in Q1 2026.
- How has Agios Pharmaceuticals's operating lease liabilities (current) changed year-over-year?
- Agios Pharmaceuticals's operating lease liabilities (current) increased by 9.4% year-over-year, from $17.2M to $18.81M.
- What is the long-term trend for Agios Pharmaceuticals's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's operating lease liabilities (current) has grown at a 21.0% compound annual growth rate (CAGR), from $7.09M to $18.39M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.